Optimising remote sampling of NfL and GFAP using blood cards in the Genetic Frontotemporal Dementia Initiative (GENFI) cohort

Sophie E. Goldsmith¹, Imogen J. Swift^{1,2}, Lara Oh¹, Rhiannon Laban², Henrik Zetterberg¹⁻⁶ Aitana Sogorb-Esteve^{1,2}, Jonathan D. Rohrer^{1,2}

I. Background

Remote collection of blood samples provides a more accessible and cost-effective alternative to regular clinic visits and allows for more frequent measures to be taken.

• The aim of this current study was to assess whether neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), can be measured using dried blood cards and to optimise the protocol for this.


2. Methods

- Blood samples were collected via venepuncture from 40 pre-symptomatic GENFI participants (see Table I for gene group breakdown).
- One sample for plasma analysis and one sample was used to pipette whole blood on to a blood card.
- NfL and GFAP concentrations were subsequently quantified using the Simoa multiplex Neurology 4-Plex A (N4PA) assay.

C9	GRN	MAPT	ТВК
22	6		

Table I. Participants' gene groups

1. Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, UCL Queen Square Institute of Neurology, University College London, UCL Queen Square Institute of Neurology, University College London, UCL Queen Square Institute of Neurology, University College London, UCL Queen Square Institute of Neurology, University College London, UCL Queen Square Institute of Neurology, University College London, UCL Queen Square Institute of Neurology, University College London, UCL Queen Square Institute of Neurology, University College London, UCL Queen Square Institute of Neurology, University College London, UCL Queen Square Institute of Neurology, University College London, UCL Queen Square Institute of Neurology, University College London, UCL Queen Square Institute of Neurology, University College London, UCL Queen Square Institute of Neurology, University College London, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom. 3. Laboratory of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden. 4. Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, SE- 43180 Mölndal, Sweden. 5. Department of Psychiatry and Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. 6. Clinical Neuroschemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden 7. Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.



3. Results

- In this pilot cohort, blood card GFAP concentration very strongly correlated with matched plasma GFAP (r = 0.878, p<0.0001).
- However, blood card NfL concentration did not correlate with matched plasma NfL (r = 0.238, p = 0.1394).
- Incubation temperature impacted total protein concentration in the blood cards, but freeze-thaw and incubation time did not.

4. Conclusion

This pilot study shows:

- **GFAP** concentrations can be successfully quantified using dried blood cards and GFAP results strongly correlate with plasma measures.
- Future work will investigate improving the methodology, particularly for the NfL assay, as well as assessing samples obtained through lancet-based fingerprick collection and the feasibility of home collection.

Figure I. Simoa **HD-X** analyser was loaded with plasma and dried blood spot samples

